These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Stone JM Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330 [TBL] [Abstract][Full Text] [Related]
4. The cytokine model of schizophrenia: emerging therapeutic strategies. Girgis RR; Kumar SS; Brown AS Biol Psychiatry; 2014 Feb; 75(4):292-299. PubMed ID: 24439555 [TBL] [Abstract][Full Text] [Related]
5. The association between Beck K; Arumuham A; Brugger S; McCutcheon RA; Veronese M; Santangelo B; McGinnity CJ; Dunn J; Kaar S; Singh N; Pillinger T; Borgan F; Sementa T; Neji R; Jauhar S; Aigbirhio F; Boros I; Turkheimer F; Hammers A; Lythgoe D; Stone J; Howes OD J Psychopharmacol; 2022 Sep; 36(9):1051-1060. PubMed ID: 36120998 [TBL] [Abstract][Full Text] [Related]
6. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Javitt DC Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858 [TBL] [Abstract][Full Text] [Related]
12. Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention. Gomes FV; Grace AA Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922888 [TBL] [Abstract][Full Text] [Related]
13. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Salavati B; Rajji TK; Price R; Sun Y; Graff-Guerrero A; Daskalakis ZJ Schizophr Bull; 2015 Jan; 41(1):44-56. PubMed ID: 25249654 [TBL] [Abstract][Full Text] [Related]
14. [To Test Glutamate Hypothesis for Schizophrenia Utilizing Proton Magnetic Resonance Spectroscopy]. Tsugawa S; Nakajima SL Brain Nerve; 2017 Sep; 69(9):1035-1040. PubMed ID: 28900066 [TBL] [Abstract][Full Text] [Related]
15. Mutations of the glycine cleavage system genes possibly affect the negative symptoms of schizophrenia through metabolomic profile changes. Yoshikawa A; Nishimura F; Inai A; Eriguchi Y; Nishioka M; Takaya A; Tochigi M; Kawamura Y; Umekage T; Kato K; Sasaki T; Ohashi Y; Iwamoto K; Kasai K; Kakiuchi C Psychiatry Clin Neurosci; 2018 Mar; 72(3):168-179. PubMed ID: 29232014 [TBL] [Abstract][Full Text] [Related]
16. In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance Spectroscopy at 4T. Kim SY; Kaufman MJ; Cohen BM; Jensen JE; Coyle JT; Du F; Öngür D Biol Psychiatry; 2018 Mar; 83(6):484-491. PubMed ID: 29031411 [TBL] [Abstract][Full Text] [Related]
17. Multiprobe molecular imaging of an NMDA receptor hypofunction rat model for glutamatergic dysfunction. Kosten L; Verhaeghe J; Verkerk R; Thomae D; De Picker L; Wyffels L; Van Eetveldt A; Dedeurwaerdere S; Stroobants S; Staelens S Psychiatry Res Neuroimaging; 2016 Feb; 248():1-11. PubMed ID: 26803479 [TBL] [Abstract][Full Text] [Related]
18. Impaired Prefrontal Cortical Dopamine Release in Schizophrenia During a Cognitive Task: A [11C]FLB 457 Positron Emission Tomography Study. Rao N; Northoff G; Tagore A; Rusjan P; Kenk M; Wilson A; Houle S; Strafella A; Remington G; Mizrahi R Schizophr Bull; 2019 Apr; 45(3):670-679. PubMed ID: 29878197 [TBL] [Abstract][Full Text] [Related]
19. Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. Marsman A; van den Heuvel MP; Klomp DW; Kahn RS; Luijten PR; Hulshoff Pol HE Schizophr Bull; 2013 Jan; 39(1):120-9. PubMed ID: 21746807 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in the MAM model for schizophrenia. Gulchina Y; Xu SJ; Snyder MA; Elefant F; Gao WJ J Neurochem; 2017 Nov; 143(3):320-333. PubMed ID: 28628228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]